IL-6: Insights into Novel Biological Activities

Clinical Immunology and Immunopathology - Tập 85 Số 1 - Trang 16-20 - 1997
Beverly E. Barton1
1Department of Surgery, UMDNJ-NJMS, Newark 07103, USA.

Tóm tắt

Từ khóa


Tài liệu tham khảo

Hirano, 1986, Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin, Nature, 324, 73, 10.1038/324073a0

Sehgal, 1987, Human chromosome 7 carries the β2, Proc. Natl. Acad. Sci. USA, 84, 3633

Leutz, 1989, Molecular cloning of the chicken myelomonocytic growth factor (cMGF) reveals relationship to interleukin-6 and granulocyte colony stimulating factor, EMBO, 8, 175, 10.1002/j.1460-2075.1989.tb03362.x

Bazan, 1990, Haemopoietic receptors and helical cytokines, Immunol. Today, 11, 350, 10.1016/0167-5699(90)90139-Z

Taga, 1989, Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130, Cell, 58, 573, 10.1016/0092-8674(89)90438-8

Davis, 1993, LIFRβ and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor, Science, 260, 1805, 10.1126/science.8390097

Gearing, 1992, The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor, Science, 255, 1434, 10.1126/science.1542794

Gearing, 1992, Oncostatin M binds the high-affinity leukemia inhibitory factor receptor, New Biol., 4, 61

Hilton, 1994, Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction, EMBO J., 13, 4765, 10.1002/j.1460-2075.1994.tb06802.x

Yin, 1993, Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction, J. Immunol., 151, 2555, 10.4049/jimmunol.151.5.2555

Murakami, 1993, IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase, Science, 260, 1808, 10.1126/science.8511589

Stahl, 1994, Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components, Science, 263, 92, 10.1126/science.8272873

Kumanogoh, 1997, Impairment of antigen-specific antibody production in transgenic mice expressing a dominant-negative form of gp130, Proc. Natl. Acad. Sci. USA, 94, 2478, 10.1073/pnas.94.6.2478

Yoshida, 1996, Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders, Proc. Natl. Acad. Sci. USA, 93, 407, 10.1073/pnas.93.1.407

Jansen, 1992, Interleukin 6 is a permissive factor for monocytic colony formation by human hematopoietic progenitor cells, J. Exp. Med., 175, 1151, 10.1084/jem.175.4.1151

Dalrymple, 1995, IL-6 deficient mice are highly susceptible toL. monocytogenes, Infect. Immun., 63, 2262, 10.1128/IAI.63.6.2262-2268.1995

Suzuki, 1997, Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice, Infect. Immun., 65, 2339, 10.1128/IAI.65.6.2339-2345.1997

F. A. Houssiau, P. G. Coulie, D. Olive, J. Van Snick, Synergistic activation of human T cells by interleukin 1 and interleukin 6, Eur. J. Immunol. 18, 1988

Garman, 1987, B-cell-stimulatory factor 2 (β2, Proc. Natl. Acad. Sci. USA, 84, 7629, 10.1073/pnas.84.21.7629

Tosato, 1988, Interferon-β2, J. Immunol., 141, 1556, 10.4049/jimmunol.141.5.1556

Lotz, 1988, B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes, J. Exp. Med., 167, 1253, 10.1084/jem.167.3.1253

Cueppens, 1988, Human T cell activation with phytohemagglutinin, J. Immunol., 141, 3868, 10.4049/jimmunol.141.11.3868

Duits, 1992, Synergism of interleukin 6 and 1α,25-dihydroxyvitamin D3, J. Leukocyte Biol., 51, 237, 10.1002/jlb.51.3.237

Hudak, 1992, Anti-IL-6 antibodies suppress myeloid cell production and the generation of CFU-c in long term bone marrow cultures, Exp. Hematol., 20, 412

Ulich, 1989, In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs, Blood, 73, 108, 10.1182/blood.V73.1.108.108

Takai, 1988, B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes, J. Immunol., 140, 508, 10.4049/jimmunol.140.2.508

Ming, 1989, Interleukin-6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium, J. Mol. Cell. Immunol., 4, 203

Galandrini, 1991, Interleukin-6 is constitutively produced by human CTL clones and is required to maintain their cytolytic function, Cell. Immunol., 138, 11, 10.1016/0008-8749(91)90128-X

Bass, 1993, Heterogeneous mechanisms of human cytotoxic T lymphocyte generation, J. Immunol., 151, 2895, 10.4049/jimmunol.151.6.2895

Luger, 1989, IFN-β2, J. Immunol., 143, 1206, 10.4049/jimmunol.143.4.1206

Moskowitz, 1997, Efficient immunity againstLeishmania major, Infect. Immun., 65, 2448, 10.1128/IAI.65.6.2448-2450.1997

Mihara, 1991, Interleukin 6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis, Eur. J. Immunol., 21, 2327, 10.1002/eji.1830211006

Muraguchi, 1988, The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells, J. Exp. Med., 167, 332, 10.1084/jem.167.2.332

Okada, 1983, B cell growth factor (BCGF) and B cell differentiation factor from human T hybridomas, J. Exp. Med., 157, 583, 10.1084/jem.157.2.583

Takatsuki, 1988, Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo, J. Immunol., 141, 3072, 10.4049/jimmunol.141.9.3072

Aarden, 1985, A growth factor for B cell hybridomas produced by human monocytes, Lymphokines, 10, 175

Aarden, 1987, Production of hybridoma growth factor by human monocytes, Eur. J. Immunol., 17, 1411, 10.1002/eji.1830171004

Aarden, 1989, Hybridoma growth factor, Ann. N.Y. Acad. Sci., 557, 192, 10.1111/j.1749-6632.1989.tb24012.x

Sehgal, 1987, Human β2, Science, 235, 731, 10.1126/science.3492764

Suematsu, 1989, IgG1 plasmacytosis in interleukin 6 transgenic mice, Proc. Natl. Acad. Sci. USA, 86, 7547, 10.1073/pnas.86.19.7547

Preiser, 1991, Interleukin-6 administration has no acute hemodynamic or hematologic effects in the dog, Cytokine, 3, 1, 10.1016/1043-4666(91)90002-U

Neta, 1988, Comparison ofin vivo, Lymphokine Res., 7, 403

Asano, 1990, In vivo, Blood, 75, 1602, 10.1182/blood.V75.8.1602.1602

Crowl, 1991, Induction of phospholipase A2, J. Biol. Chem., 266, 2647, 10.1016/S0021-9258(18)52293-6

Vadas, 1983, Involvement of circulating phospholipase A2, Can. J. Physiol. Pharmacol., 6, 561, 10.1139/y83-086

Vadas, 1988, Extracellular phospholipase A2, Agents Actions, 24, 320, 10.1007/BF02028289

Aderka, 1989, IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice, J. Immunol., 143, 3517, 10.4049/jimmunol.143.11.3517

Aderka, 1993, Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-α, Blood, 81, 2076, 10.1182/blood.V81.8.2076.2076

Ulich, 1991, Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6, J. Immunol., 146, 2316, 10.4049/jimmunol.146.7.2316

Riedy, 1992, Inhibitory role of interleukin-6 in macrophage proliferation, J. Leukocyte Biol., 52, 125, 10.1002/jlb.52.1.125

Ritchie, 1997, Adenosine increases interleukin 6 release and decreases tumor necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages, Cytokine, 9, 187, 10.1006/cyto.1996.0153

Barrett, 1994, Discrimination of A12in vivo, J. Pharmacol. Exp. Ther., 268, 1166

Cronstein, 1993, The antiinflammatory mechanism of methotrexate, J. Clin. Invest., 92, 2675, 10.1172/JCI116884

Chen, 1993, Interleukin-6 production in a murine model ofPneumocystis carinii, Infect. Immun., 61, 97, 10.1128/IAI.61.1.97-102.1993

Bermudez, 1992, Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages, Infect. Immun., 60, 4245, 10.1128/IAI.60.10.4245-4252.1992

Denis, 1992, Interleukin-6 in mouse hypersensitivity pneumonitis: Changes in lung free cells following depletion of endogenous IL-6 or direct administration of IL-6, J. Leukocyte Biol., 52, 197, 10.1002/jlb.52.2.197

Ulich, 1991, Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation, Am. J. Pathol., 138, 1097

Lotz, 1991, Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating factor activity (TIMP-1/EPA), J. Biol. Chem., 266, 2017, 10.1016/S0021-9258(18)52202-X

Barton, 1993, The protective role of IL-6 in a septic shock model, Infect. Immun., 61, 1496, 10.1128/IAI.61.4.1496-1499.1993

Barton, 1996, Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model, Infect. Immun., 64, 714, 10.1128/IAI.64.3.714-718.1996

Baumann, 1987, Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells, J. Biol. Chem., 262, 9756, 10.1016/S0021-9258(18)47999-9

Baumann, 1993, Suramin inhibits the stimulation of acute phase protein genes by IL-6-type cytokines in rat hepatoma cells, J. Immunol., 151, 1456, 10.4049/jimmunol.151.3.1456

Perlstein, 1991, Interleukin-1 and interleukin-6 act synergistically to stimulate the release of adrenocorticotropic hormonein vivo, Lymphokine Cytokine Res., 10, 141

Salas, 1990, Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells, Clin. Exp. Immunol., 79, 470, 10.1111/j.1365-2249.1990.tb08114.x

Starnes, 1990, Anti-IL-6 monoclonal antibodies protect against lethalEscherichia coli, J. Immunol., 145, 4185, 10.4049/jimmunol.145.12.4185

May, 1992, High levels of “complexed” interleukin-6 in human blood, J. Biol. Chem., 267, 19698, 10.1016/S0021-9258(18)41831-5

May, 1993, Antibodies chaperone circulating IL-6, J. Immunol., 151, 3225, 10.4049/jimmunol.151.6.3225

Barton, 1990, IL-3 and IL-6 do not induce bone resorption in vitro, Cytokine, 2, 217, 10.1016/1043-4666(90)90019-P

Al-Humidan, 1991, Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae, J. Bone Miner. Res., 6, 3, 10.1002/jbmr.5650060103

Ishimi, 1990, IL-6 is produced by osteoblasts and induces bone resorption, J. Immunol., 145, 3297, 10.4049/jimmunol.145.10.3297

Lowik, 1989, Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis, Biochem. Biophys. Res. Commun., 162, 1546, 10.1016/0006-291X(89)90851-6

Bertolini, 1994, Interleukin 6 production in fetal rat long bone cultures is correlated with PGE2, Cytokine, 6, 368, 10.1016/1043-4666(94)90060-4

Binkley, 1994, Effects of recombinant human interleukin-6 administration on bone in rhesus monkeys, J. Bone Miner. Res., 13, 221

Most, 1995, In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis, J. Bone Miner. Res., 10, 1523, 10.1002/jbmr.5650101013

Girasole, 1992, 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens, J. Clin. Invest., 89, 883, 10.1172/JCI115668

Miyaura, 1995, Endogenous bone-resorbing factors in estrogen deficiency: Cooperative effects of IL-1 and IL-6, J. Bone Miner. Res., 10, 1365, 10.1002/jbmr.5650100914

Tamura, 1993, Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6, Proc. Natl. Acad. Sci. USA, 90, 11924, 10.1073/pnas.90.24.11924

Kurihara, 1990, IL-6 stimulates osteoclast-like multinucleated cell formation in long term human bone marrow cultures by inducing IL-1 release, J. Immunol., 144, 4226, 10.4049/jimmunol.144.11.4226

Udagawa, 1995, Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors, J. Exp. Med., 182, 1461, 10.1084/jem.182.5.1461

Roodman, 1992, Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone, J. Clin. Invest., 89, 46, 10.1172/JCI115584

Roodman, 1994, Biology of the osteoclast in Paget's disease, Semin. Arthritis Rheum., 23, 235, 10.1016/0049-0172(94)90043-4

Hoyland, 1994, 6 receptor, and IL-6 nuclear factor gene expression in Paget's disease, J. Bone Miner. Res., 9, 75, 10.1002/jbmr.5650090111

Strassman, 1992, Evidence for the involvement of interleukin 6 in experimental cancer cachexia, J. Clin. Invest., 89, 1681, 10.1172/JCI115767

Strassman, 1993, Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia, J. Clin. Invest., 92, 2152, 10.1172/JCI116816

Oldenburg, 1993, Cachexia and the acute-phase response in inflammation are regulated by interleukin-6, Eur. J. Immunol., 23, 1889, 10.1002/eji.1830230824

Strassman, 1993, The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo, Cytokine, 5, 285, 10.1016/1043-4666(93)90058-D

Black, 1991, Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice, Endocrinology, 128, 2657, 10.1210/endo-128-5-2657